Myelodysplastic Syndrome Treatment Market, by Drug (Lenalidomide, Decitabine, Azacitidine, and Phase 3 Drugs), by Route of Administration (Injection and Oral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by

Myelodysplastic Syndrome Treatment Market, by Drug (Lenalidomide, Decitabine, Azacitidine, and Phase 3 Drugs), by Route of Administration (Injection and Oral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Myelodysplastic syndromes are a group of cancers in which immature blood cells in the bone marrow do not mature or become healthy blood cells. The different types of myelodysplastic syndromes are diagnosed based on certain changes in the blood cells and bone marrow. Myelodysplastic syndromes (MDS) are a type of rare blood cancers where don't have enough healthy blood cells. It is also known as myelodysplasia. There are several different types of MDS. In MDS, some of the cells in the bone marrow are abnormal (dysplastic) and have problems making new blood cells. Several of the blood cells formed by these bone marrow cells are defective. Defective cells often die earlier than normal cells, and the body also destroys some abnormal blood cells, leaving the person without enough normal blood cells. Different cell types can be affected, although the most common finding in Myelodysplastic syndromes is a shortage of red blood cells (anemia). Therapy-related MDS is a subtype of Myelodysplastic syndromes. It is caused by treatment with chemotherapy or radiation therapy for a previous cancer. In the U.S., the number of new diagnoses of Myelodysplastic syndromes and therapy-related Myelodysplastic syndromes are both rising. This is because older people make up a growing segment of the population and people now live longer after treatment for cancer.

Market Dynamics

Increasing launch and approval of Azacitidine in key regions namely North America, Latin America, Europe, Asia Pacific, and Africa etc. is expected to drive growth of Azacitidine segment of the myelodysplastic syndrome treatment market over the forecast period. For instance, in February 2018, BeiGene, Ltd. Biotechnology Company announced the commercial availability of VIDAZ (azacitidine for injection) in China. VIDAZA is approved in China for patients with intermediate-2 / high-risk myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) with 20-30% bone marrow blasts, and chronic myelomonocytic leukemia (CMML). It is marketed in China by BeiGene under an exclusive license from Celgene Corporation (Pharmaceutical Company).

Key features of the study:

  • This report provides an in-depth analysis of the global myelodysplastic syndrome (MDS) treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global myelodysplastic syndrome (MDS) treatment market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Celgene Corporation, Otsuka Pharmaceutical Co., Ltd. Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Mylan NV, Cipla Limited, Acceleron Pharma, Inc., Aprea Therapeutics, FibroGen Inc., Onconova Therapeutics Inc., and Geron.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global myelodysplastic syndrome (MDS) treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts1
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global myelodysplastic syndrome (MDS) treatment market
Detailed Segmentation:
  • Global Myelodysplastic Syndrome (MDS) Treatment Market, By Drug :
  • Lenalidomide
  • Decitabine
  • Azacitidine
  • Phase 3 Drugs
  • Global Myelodysplastic Syndrome (MDS) Treatment Market, By Route of Administration:
  • Injection
  • Oral
  • Global Myelodysplastic Syndrome (MDS) Treatment Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Global Myelodysplastic Syndrome (MDS) Treatment Market, By Region:
  • North America
  • By Country
  • U.S.
  • Canada
  • Latin America
  • By Country
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • By Country
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • By Country
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • By Country
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • By Country
  • South Africa
  • Central Africa
  • North Africa
  • Company Profiles
  • Celgene Corporation
  • Company Highlights
  • Products Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Otsuka Pharmaceutical Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Limited
  • Reddy's Laboratories Ltd.
  • Mylan NV
  • Cipla Limited
  • Acceleron Pharma, Inc.
  • Aprea Therapeutics
  • FibroGen Inc.
  • Onconova Therapeutics Inc.
  • Geron
“*” marked represents similar segmentation in other categories in the respective section.


1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Snapshot, By Drug
Market Snapshot, By Route of Administration
Market Snapshot, By Distribution Channel
Market Snapshot, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Restraints
Market Opportunities
Impact Analysis
Market Trends
Recent Developments
Acquisitions and Partnerships Scenario
Technology Overview
Regulatory Scenario
Pricing Analysis
PEST Analysis
4. Global Myelodysplastic Syndrome (MDS) Treatment Market- Impact of Coronavirus (Covid-19) Pandemic
Overall Impact
Government Initiatives
COVID-19 Impact on the market
5. Global Myelodysplastic Syndrome (MDS) Treatment Market, By Drug, 2017 – 2030, (US$ Million)
Overview
Market Share Analysis, 2022 and 2030 (%)
Y-o-Y Growth Analysis, 2017 – 2030
Segment Trends
Lenalidomide
Overview
Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
Decitabine
Overview
Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
Azacitidine
Overview
Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
Phase 3 Drugs
Overview
Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
6. Global Myelodysplastic Syndrome (MDS) Treatment Market, By Route of Administration, 2017 – 2030, (US$ Million)
Overview
Market Share Analysis, 2022 and 2030 (%)
Y-o-Y Growth Analysis, 2017 – 2030
Segment Trends
Injection
Overview
Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
Oral
Overview
Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
7. Global Myelodysplastic Syndrome (MDS) Treatment Market, By Distribution Channel, 2017 – 2030, (US$ Million)
Overview
Market Share Analysis, 2022 and 2030 (%)
Y-o-Y Growth Analysis, 2017 – 2030
Segment Trends
Hospital Pharmacies
Overview
Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
Retail Pharmacies
Overview
Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
Online Pharmacies
Overview
Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
8. Global Myelodysplastic Syndrome (MDS) Treatment Market, By Region, 2017 – 2030, (US$ Million)
Introduction
Market Share Analysis, By Region, 2022 and 2030 (%)
Y-o-Y Growth Analysis, For Regions, 2017–2030
Regional Trends
North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug, 2017 - 2030, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
U.S.
Canada
Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug, 2017 - 2030, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug, 2017 - 2030, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug, 2017 - 2030, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug, 2017 - 2030, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
GCC
Israel
Rest of Middle East
Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug, 2017 - 2030, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 – 2030, (US$ Million)
North Africa
Central Africa
South Africa
9. Competitive Landscape
Heat Map Analysis
Company Profiles
Celgene Corporation
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
Otsuka Pharmaceutical Co., Ltd.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
Teva Pharmaceutical Industries Ltd.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
Sun Pharmaceutical Industries Limited
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
Dr. Reddy's Laboratories Ltd.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
Mylan NV
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
Cipla Limited
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
Acceleron Pharma, Inc.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
Aprea Therapeutics
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
FibroGen Inc.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
Onconova Therapeutics Inc.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
Geron
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
Analyst Views
10. Section
References
Research Methodology
About Us
*Browse 32 market data tables and 35 figures on "Global Myelodysplastic Syndrome (MDS) Treatment Market” - forecast to 2030

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings